{"id":61903,"date":"2026-05-07T23:53:44","date_gmt":"2026-05-07T23:53:44","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/61903\/"},"modified":"2026-05-07T23:53:44","modified_gmt":"2026-05-07T23:53:44","slug":"roche-to-acquire-pathai-for-up-to-1-05b","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/61903\/","title":{"rendered":"Roche to acquire Pathai for up to $1.05B"},"content":{"rendered":"<p>Roche Holding AG has agreed to acquire Pathai Inc. for up to $1.05 billion in a bid to strengthen its position in digital pathology and enhance its biopharma services. The move builds on a partnership established between the two companies in 2021, and expanded in 2024, to include the development of AI-enabled companion diagnostic algorithms.<\/p>\n<p><a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/84-bioworld\" rel=\"nofollow noopener\" target=\"_blank\">BioWorld<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/214-deals-and-m-a\" rel=\"nofollow noopener\" target=\"_blank\">Deals and M&amp;A<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/85-medical-technology\" rel=\"nofollow noopener\" target=\"_blank\">Medical technology<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/325-diagnostics\" rel=\"nofollow noopener\" target=\"_blank\">Diagnostics<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/239-cancer\" rel=\"nofollow noopener\" target=\"_blank\">Cancer<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/260-oncology\" rel=\"nofollow noopener\" target=\"_blank\">Oncology<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/396-europe\" rel=\"nofollow noopener\" target=\"_blank\">Europe<\/a> <a class=\"topic\" href=\"https:\/\/www.bioworld.com\/topics\/401-u-s\" rel=\"nofollow noopener\" target=\"_blank\">U.S.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Roche Holding AG has agreed to acquire Pathai Inc. for up to $1.05 billion in a bid to&hellip;\n","protected":false},"author":2,"featured_media":4863,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[124],"tags":[34089,8086,2112,14235,8568,1176,7095,197,9063,265,34090,134,473,2278],"class_list":{"0":"post-61903","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-roche","8":"tag-aisight-image-management-system","9":"tag-bioworld","10":"tag-cancer","11":"tag-companion-diagnostics","12":"tag-deals-and-ma","13":"tag-diagnostics","14":"tag-digital-pathology","15":"tag-europe","16":"tag-medical-technology","17":"tag-oncology","18":"tag-pathai-inc","19":"tag-roche","20":"tag-roche-holding-ag","21":"tag-u-s"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116535991060108785","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/61903","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=61903"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/61903\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/4863"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=61903"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=61903"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=61903"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}